Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azstarys in Children 4-12 with ADHD
NCT05685732Phase 4Completed
- Sponsor
- Corium
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of serdexmethylphenidate + dexmethylphenidate in attention deficit hyperactivity disorder (ADHD) (4 cohorts), sponsored by Corium. Primary endpoint: ADHD Rating Scale Total Score at 4 weeks. Started Mar 2023; status: completed.
02
Drugs
serdexmethylphenidate + dexmethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05685732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685732.